Mirvetuximab soravtansine-gynx

Enquire Best Price to Buy Mirvetuximab soravtansine-gynx in India

About API Mirvetuximab soravtansine-gynx:

Mirvetuximab soravtansine-gynx is approved for use in adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have received one to three prior systemic therapies. These related cancer types are generally treated in a similar manner. Platinum-resistant disease refers to cancer that returns or progresses within six months of platinum-based chemotherapy. FRα is a protein present on the surface of certain cancer cells, and Mirvetuximab soravtansine-gynx specifically targets this protein to deliver its anti-cancer action directly to the tumor. It is intended for patients whose disease has progressed after previous treatments and whose tumors have been confirmed to express FRα.